scholarly journals New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?

2021 ◽  
pp. 1-10
Author(s):  
Bingnan Zhang ◽  
Samuel R. Birer ◽  
Mikhail Dvorkin ◽  
Jolly Shruti ◽  
Lauren Byers
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Current Treatment ◽  
Small Cell ◽  
Personalized Treatment ◽  
Small Cell Lung ◽  
Treatment Standards ◽  
Treatment Paradigm

Small cell lung cancer (SCLC) is an aggressive form of lung cancer with a 5-year survival rate of less than 7%. In contrast to non–small cell lung cancer, SCLC has long been treated as a homogeneous disease without personalized treatment options. In recent years, the incorporation of immunotherapy into the treatment paradigm has brought moderate benefit to patients with SCLC; however, more effective therapies are urgently needed. In this article, we describe the current treatment standards and emerging therapeutic approaches for the treatment of SCLC. We also discuss promising biomarkers in SCLC and the recently discovered four subtypes of SCLC, each with its unique therapeutic vulnerability. Lastly, we discuss the advances in radiation therapy for the treatment of SCLC.

scholarly journals Managing Patients With Relapsed Small-Cell Lung Cancer

2018 ◽  
Vol 14 (6) ◽  
pp. 359-366 ◽  
Author(s):  
Jun Gong ◽  
Ravi Salgia
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Sequential Therapy ◽  
Initial Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Treatment Paradigm

Despite high response rates to initial therapy, relapses are common in patients with small-cell lung cancer (SCLC). Systemic therapy after first-line failure remains important in the treatment paradigm of SCLC. Reinitiation of a previously administered first-line chemotherapy regimen is recommended for relapse > 6 months from completion of initial therapy. For relapse ≤ 6 months of initial therapy, sequential therapy with single agents is recommended. Clinical trial enrollment should be considered at all stages of treatment of SCLC. This review highlights the available treatment options in relapsed SCLC. In particular, we focus on prospective clinical trials demonstrating activity for the most commonly used agents in this setting. We end with a discussion on future directions and emerging targets with potential to improve outcomes in relapsed SCLC.

scholarly journals Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Evgenii Skurikhin ◽  
Olga Pershina ◽  
Mariia Zhukova ◽  
Darius Widera ◽  
Natalia Ermakova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Current Treatment ◽  
Small Cell ◽  
Diagnosis And Treatment ◽  
Chronic Obstructive ◽  
Small Cell Lung

Despite the increasing urgency of the problem of treating small cell lung cancer (SCLC), information on the causes of its development is fragmentary. There is no complete understanding of the features of antitumor immunity and the role of the microenvironment in the development of SCLC resistance. This impedes the development of new methods for the diagnosis and treatment of SCLC. Lung cancer and chronic obstructive pulmonary disease (COPD) have common pathogenetic factors. COPD is a risk factor for lung cancer including SCLC. Therefore, the search for effective approaches to prevention, diagnosis, and treatment of SCLC in patients with COPD is an urgent task. This review provides information on the etiology and pathogenesis of SCLC, analyses the effectiveness of current treatment options, and critically evaluates the potential of chimeric antigen receptor T cells therapy (CART therapy) in SCLC. Moreover, we discuss potential links between lung cancer and COPD and the role of endothelium in the development of COPD. Finally, we propose a new approach for increasing the efficacy of CART therapy in SCLC.

Current and evolving treatment options for limited stage small cell lung cancer

2006 ◽  
Vol 18 (2) ◽  
pp. 162-172 ◽  
Author(s):  
Carrie B Lee ◽  
David E Morris ◽  
Daniel B Fried ◽  
Mark A Socinski
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage

Treatment options for relapsed small-cell lung cancer

2007 ◽  
Vol 18 (3) ◽  
pp. 255-261 ◽  
Author(s):  
Hatem A. Azim ◽  
Apar Kishor Ganti
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document